Monte Rosa Therapeutics (GLUE) Short-term Investments (2022 - 2023)
Monte Rosa Therapeutics (GLUE) posted quarterly Short-term Investments of $960000.0 for Q1 2023, little changed quarter-over-quarter from $960000.0 in Q4 2022.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Short-term Investments (2022 - 2023) Analysis & Trends
Monte Rosa Therapeutics' Short-term Investments history runs 2 years deep, the most recent figure standing at $960000.0 for Q1 2023.
- In Q1 2023, Short-term Investments changed N/A year-over-year to $960000.0; the TTM figure through Mar 2023 stood at $960000.0 (changed N/A YoY), while the FY2022 annual figure was $960000.0, changed N/A from the prior year.
- Short-term Investments for Q1 2023 stood at $960000.0, roughly flat from $960000.0 in the prior quarter.
- The five-year high for Short-term Investments was $960000.0 in Q3 2022, with the low at $960000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 960,000.00 |
| Dec 31, 2022 | 960,000.00 |
| Sep 30, 2022 | 960,000.00 |